Enliven Therapeutics Inc (ELVN)
24.00
+0.96
(+4.17%)
USD |
NASDAQ |
May 20, 16:00
24.02
+0.02
(+0.08%)
After-Hours: 20:00
Enliven Therapeutics Total Liabilities (Quarterly): 25.06M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 25.06M |
| December 31, 2023 | 25.96M |
| September 30, 2023 | 12.29M |
| June 30, 2023 | 9.507M |
| Date | Value |
|---|---|
| March 31, 2023 | 11.45M |
| December 31, 2022 | 160.12M |
| September 30, 2022 | 158.89M |
| December 31, 2021 | 156.22M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
9.507M
Minimum
Jun 2023
160.12M
Maximum
Dec 2022
69.94M
Average
25.51M
Median
Total Liabilities (Quarterly) Benchmarks
| Eyenovia Inc | 24.36M |
| Phathom Pharmaceuticals Inc | 505.00M |
| Lantern Pharma Inc | 3.969M |
| Vincerx Pharma Inc | 11.70M |
| NKGen Biotech Inc | 75.17M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 342.78M |
| Shareholders Equity (Quarterly) | 317.71M |